Presentation A 30-year-old woman presented to her rheumatologist for left foot pain of three weeks’ duration. She was followed for systemic lupus erythematosus manifesting in arthritis and hemolytic anemia, as well as anti-nuclear antibody and Smith antibody positivity, and was treated with hydroxychloroquine and prednisone in the 2.5–10 mg per day range. She was symptom…
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…
Dozens of rheumatology leaders met with more than 100 politicos on Capitol Hill in mid-May, per the ACR’s annual Advocacy Leadership Conference. Armed with research and advocacy training concerning a handful of important issues, rheumatologists, researchers, government affairs specialists and others met with federal lawmakers, legislative aides and correspondents. The two-day conference, which featured the…
Where can patients obtain more information about their diagnoses and prescription drugs, and answers to the assortment of questions they have about living with a chronic disease once they leave the rheumatologist office? Patient education materials can be found in many places on the internet, but those looking for answers may need a helping hand…
A group led by Sarah Ringold, MD, MS, assistant professor of rheumatology at Seattle Children’s Hospital, has developed a new guideline intended to provide recommendations for the treatment and monitoring of children with juvenile idiopathic arthritis (JIA) manifesting as non-systemic polyarthritis, sacroiliitis or enthesitis.1,2 Key Updates The new recommendations appear in both Arthritis & Rheumatology…
In a recent investigation of Swedish patients, environmental triggers of the immune system are a common factor for patients with primary Sjögren’s syndrome…
In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…
WASHINGTON (Reuters)—U.S. President Donald Trump called on Congress on Thursday to pass legislation to protect patients from surprise medical bills from out-of-network doctors that can unnecessarily cost patients tens of thousands of dollars. In remarks at the White House, Trump unveiled principles the administration will send to congressional lawmakers to incorporate into a legislative package…
WASHINGTON (Reuters)—U.S. President Donald Trump slammed the pharmaceutical industry for high prices of prescription drugs on Thursday and vowed to allow U.S. states to buy medicines from other countries if they cost less. Trump, who campaigned on a platform to reduce drug prices for U.S. consumers, has taken few concrete steps to lower medication costs…
NEW YORK (Reuters Health)—Results from a substantial proportion of large, registered, randomized controlled trials (RCTs) can go unpublished for years after their completion, researchers report. “These unpublished and unreported trials include a vast number of patients, about 90,000,” Dr. John P. A. Ioannidis from Stanford University in California told Reuters Health. “Many people think that…